Protein kinase C and transmitter release

Clinical and Experimental Pharmacology and Physiology

Volumn 24, Issue 8, 1997, Pages 619-623

  Majewski, H ^a   Kotsonis, P ^a   Iannazzo, L ^a   Murphy, T V ^a   Musgrave, I F ^a  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Diacylglycerol; Noradrenaline; Phorbol esters; Polymyxin B; Protein kinase C; Sympathetic; Transmitter

Indexed keywords

DIACYLGLYCEROL; NORADRENALIN; PHORBOL ESTER; PROTEIN KINASE C;

CENTRAL NERVOUS SYSTEM; CONFERENCE PAPER; ELECTROSTIMULATION; HUMAN; NEUROTRANSMITTER RELEASE; NONHUMAN; NORADRENALIN RELEASE; NORADRENERGIC NERVE; SIGNAL TRANSDUCTION;

EID: 0030801650     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.1997.tb02102.x     Document Type: Conference Paper

References (56)

1. Stabel S, Parker P. Protein kinase C. Pharmacol. Ther. 1991; 51: 71-95.
2. Nishizuka Y. Intracellular signalling by hydrolysis of phospholipids and activation of protein kinase C. Science 1992; 258: 607-14.
3. Watson S, Girdlestone D. Trends in Pharmacological Sciences 1996 receptor and ion channel nomenclature supplement. Elsevier, Cambridge. 1996.
4. Musgrave IF, Majewski H. Effect of phorbol esters and polymyxin B on modulation of noradrenaline release in mouse atria. Naunyn-Schmiedeberg's Arch. Pharmacol. 1989; 339: 48-53.
5. Kotsonis P, Majewski H. The structural requirements for phorhol esters to enhance noradrenaline and dopamine release from rat brain cortex. Br. J. Pharmacol. 1996; 119: 115-25.
6. Schroeder GE, Kotsonis P, Musgrave IF, Majewski H. Protein kinase C involvement in maintenance and modulation of noradrenaline release in the mouse brain cortex. Br. J. Pharmacol. 1995; 116: 2757-63.
7. Guitart X, Marsal J, Solsna C. Phorhol esters induce neurotransmitter release in cholinergic synaptosomes from Torpedo electric organ. J. Neurochem. 1990; 55: 468-72.
8. Wardell CF, Cunnane TC. Biochemical machinery involved in the release of ATP from sympathetic nerve terminals. Br. J. Pharmacol. 1994; 111: 975-7.
9. Shearman MS, Sekiguchi K, Nishizuka Y. Modulation of ion channel activity: A key function of the protein kinase C enzyme family. Pharmacol. Rev. 1989; 41: 211-37.
10. Nichols RA, Haycock JW, Wang JKT, Greengard P. Phorbol ester enhancement of neurotransmitter release from rat brain synaptosomes. J. Neurochem. 1987; 48: 615-21.
11. 3H]-noradrenaline. Br. J. Pharmacol. 1988; 94: 713-20.
12. Robinson PJ. The role of protein kinase C and its neuronal substrates dephosphin. B-50 and MARCKS in neurotransmitter release. Mol. Neurobiol. 1992; 5: 87-129.
13. DeGraan PN, Hens JJ, Gispen WH. Presynaptic PKC substrate B-50 (GAP-43) and neurotransmitter release: Studies with permeated synaptosomes. Neurotoxicology 1994; 15: 41-7.
14. Johnstone SA, Hubaishy I, Waisman DM. Phosphorylation of annexin II tetramer by protein kinase C inhibits aggregation of lipid vesicles by the protein. J. Biol. Chem. 1992; 267: 25 976-81.
15. Wang W, Creutz CE. Regulation of the chromaffin granule aggregation activity of annexin 1 by phosphorylation. Biochemistry 1992; 31: 9934-9.
16. Majewski H. Modulation of noradrenaline release through activation of presynaptic β-adrenoceptors. J. Autonom. Pharmacol. 1983; 3: 47-60 (Corrigenda p. 155).
17. Rodnight R, Perrett C. Protein phosphorylation and synaptic transmission: Receptor mediated modulation of protein kinase C in a rat brain fraction enriched in synaptosomes. J. Physiol. 1986; 81: 340-8.
18. Allgaier C, Hertting G. Polymyxin B, a selective inhibitor of protein kinase C, diminishes the release of noradrenaline and the enhancement of release caused by phorbol 12,13-dibutyrate. Naunyn-Schmiedeberg's Arch. Pharmacol. 1986; 334: 218-21.
19. Daschmann B, Allgaier C, Nakov R, Hertting G. Staurosporine counteracts the phorbol-ester induced enhancement of neurotransmitter release in hippocampus. Arch. Int. Pharmacodyn. 1988; 296: 232-45.
20. Schächtele C, Rudolph C, Osswald H. Inhibition of protein kinase C (PKC) and three other protein kinases by several reference PKC inhibitors. Naunyn Schmiedeberg's Arch. Pharmacol. 1989; 340, R36.
21. Rüegg UT, Burgess GM. Staurosporine. K-252 and UCN-01: Potent but non-specific inhibitors of protein kinases. Trends Pharmacol. Sci. 1989; 10: 218-20.
22. Davis PD, Elliott LH, Harris W et al. Inhibitors of protein kinase C. 2. Substituted bisindolylmaleimides with improved potency and selectivity. J. Med. Chem. 1992; 35: 994-1001.
23. Hong DF, Huan J, Ou BR et al. Protein kinase C isoforms in muscle cells and their regulation by phorbol ester and calpain. Biochem. Biophys. Acta 1995; 1267: 45-54.
24. Foucart S, Musgrave IF, Majewski H. Long term treatment with phorbol esters suggests a permissive role for protein kinase C in the enhancement of noradrenaline release. Mol. Neuropharmacol. 1991; 1: 95-101.
25. Majewski H, Barrington M. Protein kinase C inhibitors decrease noradrenaline release evoked by high frequency nerve stimulation of rat atria. Proc. Aust. Soc. Clin. Exp. Pharmacol. Toxicol. 1994; 1; 77 (Abstract).
26. Majewski H, Hoare A, Murphy TV. Endogenous facilitation of noradrenaline release from sympathetic nerves through phospholipase C generation of diacylglycerol and activation of protein kinase C. Soc. Neurosci. Abstr. 1995; 21: 2066.
27. De Chaffoy De Courcelles D. The use of diacylglycerol kinase inhibitors for elucidating the roles of protein kinase C. Adv. Second Messenger Phosphoprotein Res. 1990; 24: 491-6.
28. Smart D, Wandless A, Lambert DG. Activation of phospholipase C in SH-SY5Y neuroblastoma cells by potassium-induced calcium entry. Br. J. Pharmacol. 1995; 116: 1797-800.
29. Starke K, Göthert M, Kilbinger H. Modulation of neurotransmitter release by presynaptic autoreceptors. Physiol. Rev. 1989; 69: 864-989.
30. Johnston H, Majewski H, Musgrave IF. Involvement of cyclic nucleotides in prejunctional modulation of noradrenaline release in mouse atria. Br. J. Pharmacol. 1987; 91: 773-81.
31. Musgrave IF, Foucart S, Majewski H. Evidence that angiotensin II enhances noradrenaline release from sympathetic nerves in mouse atria by activating protein kinase C. J. Autonom. Pharmacol. 1991; 11: 211-20.
32. 1 muscarinic receptors enhance noradrenaline release in mouse atria by activating protein kinase C. Br. J. Pharmacol. 1993; 110: 910-16.
33. Rechtman M, Majewski H. A facilitatory effect of anti-angiotensin drugs on vagal bradycardia in the pithed rat and guinea-pig. Br. J. Pharmacol. 1993; 110: 289-96.
34. Costa M, Majewski H. Evidence for facilitatory and inhibitory muscarinic receptors on postganglionic sympathetic nerves in mouse isolated atria. Br. J. Pharmacol. 1991; 102: 855-60.
35. Dekker LV, Parker PJ. Protein kinase C: A question of specificity. Trends Biochem. Sci. 1994; 19: 73-7.
36. Mochley-Rosen D, Khaner H, Lopez J, Smith BL. Intracellular receptors for activated protein kinase C: Identification of a binding site for the enzyme. J. Biol. Chem. 1991; 266: 14 866-8.
37. Leach KL, Ruff VA, Jarpe MB, Adams L, Fabbr D, Raben DM. Thrombin stimulates nuclear diacylglycerol levels and differential localization of protein kinase C isozymes in IIC9 cells. J. Biol. Chem. 1992; 267: 21 816-22.
38. Wetsel WC, Khan WA, Mechentaler I et al. Tissue and cellular distribution of the extended family of protein kinase C isoenzymes. J. Biol. Chem. 1992; 117: 121-33.
39. Buchner K. Protein kinase C in the transduction of signals toward the cell nucleus. Eur. J. Biochem. 1995; 228: 211-21.
40. Robinson PJ. Differential stimulation of protein kinase C activity by phorbol ester or calcium/phosphatidylserine in vitro and in intact synaptosomes. J. Biol. Chem. 1992; 267: 21 637-44.
41. Martiny-Baron G, Kazanietz MG, Mischak H et al. Selective inhibition of protein kinase C isozymes by the indolocarbazole Go6976. J. Biol. Chem. 1993; 268: 9194-7.
42. 1, γ, δ, and ∈ by phorbol esters of different biological activities. FEBS Lett. 1991; 288: 5-9.
43. Kazanietz MG, Areces LB, Bahador A et al. Characterisation of ligand and substrate specificity for the calcium-dependent and calcium-independent protein kinase C enzymes. J. Pharmacol. Exp. Ther. 1993; 44: 296-307.
44. 3H]12-deoxyphorbol 13-isobutyrate to phorbol ester receptor subclasses in mouse skin particulate preparations. Cancer Res. 1983; 43: 4632-7.
45. Zayed S, Sorg B, Hecker E. Structure-activity relationship of polyfunctional diterpenes of the tigliane type. VI. Planta Med. 1984; 34: 65-9.
46. Szallasi Z, Krsmanovic L, Blumberg PM. Nonpromoting 12-deoxyphorbol 13 esters inhibit phorbol 12-myristate 13-acetate induced tumor promotion in CD-1 mouse skin. Cancer Res. 1993; 53: 2507-12.
47. Hergenhahn M, Kusumoto S, Hecker E. Diterpene esters from 'Euphorbium' and their irritant and carcinogenic activity. Experientia 1974; 30: 1438-40.
48. Kazanietz MG, Krausz KW, Blumberg PM. Differential irreversible insertion of protein kinase C into phospholipid vesicles by phorbol esters and related activators. J. Biol. Chem. 1992; 267: 20 878-86.
49. Murphy TV, Kotsonis P, Majewski H. Pharmacokinetic properties of phorbol esters are important in determining biological effects. Proc. Aust. Soc. Clin. Exp. Pharmacol. Toxicol. 1996; 3: 41 (Abstract).
50. Dokas LA, Pisano MR, Schrama LH, Zwiers H, Gispen WH. Dephosphorylation of B-50 in synaptic plasma membranes. Brain Res. Bull. 1990; 24: 321-9.
51. Tanaka S. Isolation and characterization of protein kinase C from rat brain synaptosome cytoskeleton. Kobe J. Med. Sci. 1991; 37: 147-61.
52. Baird WM, Boutwell RK. Tumor-promoting activity of phorbol and four diesters of phorbol in mouse skin. Cancer Res. 1971; 31: 1074-9.
53. Fürstenberger G, Hecker E. Wirkungmechanismus cocarcinogener pflanzeninhaltsstoffe. Planta Med. 1972; 22: 241-66.
54. Hecker E. New phorbol esters and related cocarcinogens. In: Clarke RL, Cumley RW, McCay JE, Copeland MM (eds). Proceedings of the 10th International Cancer Congress. Yearbook Medical Publishers, Chicago. 1971; 213-24.
55. Zayed S, Sorg B, Hecker E. Structure activity relationship of polyfunctional diterpenes of the tigliane type. VI. Planta Med. 1984; 34: 65-9.
56. Blumberg PM, Jaken S, Konig B et al. Mechanism of action of the phorbol ester tumour promoters: Specific receptors for lipophilic ligands.